Biotechnology
Industry
Members
40 of 123
Capped at 40 by market capitalisation — 83 not shown
| Ticker | Name | Market cap |
|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | 14,974,763,008 |
| SYRE | Spyre Therapeutics, Inc. | 7,967,380,992 |
| SRRK | Scholar Rock Holding Corp | 7,039,188,992 |
| CGON | CG Oncology, Inc. | 6,589,524,992 |
| DFTX | Definium Therapeutics, Inc. | 5,506,357,248 |
| MANE | Veradermics, Inc | 4,091,528,704 |
| TNGX | Tango Therapeutics, Inc. | 3,935,365,888 |
| QURE | uniQure N.V. | 3,379,531,776 |
| ZLAB | Zai Lab Ltd | 2,927,903,232 |
| SLS | SELLAS Life Sciences Group, Inc. | 2,667,702,784 |
| TRVI | Trevi Therapeutics, Inc. | 2,392,169,472 |
| KOD | Kodiak Sciences Inc. | 2,370,681,600 |
| RAPP | Rapport Therapeutics, Inc. | 2,339,901,184 |
| NUVB | Nuvation Bio Inc. | 2,338,480,640 |
| MLYS | Mineralys Therapeutics, Inc. | 2,263,216,384 |
| URGN | UroGen Pharma Ltd. | 2,132,170,112 |
| ADMA | ADMA BIOLOGICS, INC. | 2,092,016,896 |
| AGIO | AGIOS PHARMACEUTICALS, INC. | 1,989,266,560 |
| XNCR | Xencor Inc | 1,937,649,536 |
| TSHA | Taysha Gene Therapies, Inc. | 1,880,059,520 |
| VIR | Vir Biotechnology, Inc. | 1,832,608,768 |
| ANAB | ANAPTYSBIO, INC | 1,666,365,184 |
| NVAX | NOVAVAX INC | 1,527,397,504 |
| REPL | Replimune Group, Inc. | 1,460,404,352 |
| KALV | KalVista Pharmaceuticals, Inc. | 1,437,504,000 |
| MLTX | MoonLake Immunotherapeutics | 1,275,749,248 |
| GLUE | Monte Rosa Therapeutics, Inc. | 1,141,493,248 |
| IVA | Inventiva S.A. | 1,111,418,112 |
| SLDB | Solid Biosciences Inc. | 1,047,590,656 |
| CADL | Candel Therapeutics, Inc. | 1,000,097,664 |
| GERN | GERON CORP | 970,134,848 |
| TBPH | Theravance Biopharma, Inc. | 885,214,656 |
| NGNE | Neurogene Inc. | 732,016,384 |
| XOMA | XOMA Royalty Corp | 710,155,008 |
| CTMX | CytomX Therapeutics, Inc. | 699,456,704 |
| ALLO | Allogene Therapeutics, Inc. | 697,891,584 |
| OCS | Oculis Holding AG | 677,996,416 |
| SGMT | Sagimet Biosciences Inc. | 655,773,760 |
| PRME | Prime Medicine, Inc. | 654,770,432 |
| EIKN | Eikon Therapeutics, Inc. | 594,732,032 |
Closest pairs inside this industry
60
Drawing the 40 strongest — 83 further edges are not on this diagram
| Pair | Kind | Strength |
|---|---|---|
| KOD – TRVI | Peer similarity | 1.00 |
| RAPP – KOD | Peer similarity | 1.00 |
| XOMA – CTMX | Peer similarity | 1.00 |
| RAPP – TRVI | Peer similarity | 1.00 |
| OCS – CTMX | Peer similarity | 1.00 |
| RAPP – MLYS | Peer similarity | 1.00 |
| PRME – OCS | Peer similarity | 1.00 |
| XOMA – OCS | Peer similarity | 1.00 |
| MLYS – KOD | Peer similarity | 1.00 |
| CADL – SLDB | Peer similarity | 1.00 |
| MLYS – TRVI | Peer similarity | 1.00 |
| VIR – XNCR | Peer similarity | 1.00 |
| PRME – CTMX | Peer similarity | 1.00 |
| ADMA – MLYS | Peer similarity | 1.00 |
| XOMA – PRME | Peer similarity | 1.00 |
| SGMT – NGNE | Peer similarity | 0.99 |
| ADMA – RAPP | Peer similarity | 0.99 |
| CADL – TBPH | Peer similarity | 0.99 |
| SRRK – SYRE | Peer similarity | 0.99 |
| ADMA – KOD | Peer similarity | 0.99 |
| PRME – EIKN | Peer similarity | 0.99 |
| SGMT – EIKN | Peer similarity | 0.99 |
| ADMA – TRVI | Peer similarity | 0.99 |
| ANAB – KALV | Peer similarity | 0.99 |
| SLDB – TBPH | Peer similarity | 0.99 |
| OCS – EIKN | Peer similarity | 0.99 |
| ALLO – EIKN | Peer similarity | 0.99 |
| CTMX – EIKN | Peer similarity | 0.99 |
| XOMA – TBPH | Peer similarity | 0.99 |
| TBPH – CTMX | Peer similarity | 0.99 |
| XOMA – EIKN | Peer similarity | 0.99 |
| REPL – GLUE | Peer similarity | 0.99 |
| URGN – ANAB | Peer similarity | 0.99 |
| TSHA – REPL | Peer similarity | 0.99 |
| OCS – TBPH | Peer similarity | 0.99 |
| GERN – MLTX | Peer similarity | 0.98 |
| NGNE – EIKN | Peer similarity | 0.98 |
| SLS – AGIO | Peer similarity | 0.98 |
| PRME – TBPH | Peer similarity | 0.98 |
| NVAX – ADMA | Peer similarity | 0.98 |
| XOMA – CADL | Peer similarity | 0.98 |
| QURE – TRVI | Peer similarity | 0.98 |
| KOD – QURE | Peer similarity | 0.98 |
| CADL – CTMX | Peer similarity | 0.98 |
| VIR – MLTX | Peer similarity | 0.98 |
| RAPP – QURE | Peer similarity | 0.98 |
| NVAX – SLDB | Peer similarity | 0.98 |
| CADL – OCS | Peer similarity | 0.98 |
| XOMA – SLDB | Peer similarity | 0.98 |
| NVAX – MLYS | Peer similarity | 0.98 |
| URGN – KALV | Peer similarity | 0.98 |
| MLYS – QURE | Peer similarity | 0.98 |
| SLDB – CTMX | Peer similarity | 0.98 |
| ZLAB – XNCR | Peer similarity | 0.98 |
| XNCR – MLTX | Peer similarity | 0.98 |
| CADL – NVAX | Peer similarity | 0.98 |
| PRME – CADL | Peer similarity | 0.98 |
| NVAX – RAPP | Peer similarity | 0.98 |
| OCS – SLDB | Peer similarity | 0.98 |
| NVAX – KOD | Peer similarity | 0.98 |
Edge strength is relative to the strongest edge in this view and is not comparable across views. Confidence is the mean confidence of the active evidence behind an edge, on an absolute scale. Peer-similarity edges are computed by us and are not a reported relationship; co-mention edges record that two companies appeared in the same article, which is adjacency rather than a business connection.